Lung Cancer · 2018 · 78 citations · 25 references
MedicineOncologyPharmacologyCancer ImmunologyImmunotherapyMonoclonal AntibodiesCancer ImmunotherapyCancer Survival AnalysisImmuno-oncology BiomarkersLung Cancer PharmacotherapyMonoclonal Antibody TherapyTherapeutic Monoclonal AntibodiesClinical Cohort DiscoveryDurable Clinical ResponseMonoclonal Antibodies In CancerMonoclonal Antibodies In OncologyNon-small Cell Lung Cancer ImmunotherapyNon-small Cell Lung Cancer TherapyNon-small Cell Lung Cancer TreatmentProgrammed Cell Death Protein 1 (Pd-1) Pathway
25
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
Martin Reck, Delvys Rodríguez‐Abreu, Andrew Robinson et al. · New England Journal of Medicine · 2016 · 10.1K citations · Full text
Medicine, Oncology, Pharmacology +17
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
H. Borghaei, L. Paz-Ares, Leora Horn et al. · New England Journal of Medicine · 2015 · 9.5K citations · Full text
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Dung T. Le, Jennifer N. Uram, Hao Wang et al. · New England Journal of Medicine · 2015 · 9.4K citations · Full text
Life Sciences, Immunology, Oncology +17
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Julie R. Brahmer, Karen L. Reckamp, Lucio Crinò et al. · New England Journal of Medicine · 2015 · 8.6K citations · Full text
Pharmacy, Oncology, Pharmacotherapy +15